



COVID-19 Update

Jakarta Japan Club - September 2021



COVID-19 GLOBAL PORTRAIT

New studies hint that the coronavirus may be evolving to become more airborne

The virus appears to spread through the air, but masks reduce the amount of infectious virus

WHO says Covid misinformation is a major factor driving pandemic around the world

PUBLISHED TUE, AUG 24 2021-3:38 PM EDT
UPDATED TUE, AUG 24 2021-7:22 PM EDT

 **Rich Mendez**
@RICHMENDEZCNBC

SHARE    

Asia Pacific

Red Cross sounds vaccines alarm as Covid deaths in south-east Asia soar

The Delta variant is wreaking havoc in the poorly vaccinated region, which has recorded 38,522 deaths in the past fortnight

Covid-19 New Cases in Malaysia Surpass Indonesia in Only 3 Days

Translator: [internship](#)
Editor: [Petir Garda Bhwana](#)

26 August 2021 13:17 WIB




COVID-19: UK records highest total of weekly coronavirus-related deaths since March

There were 652 coronavirus-related deaths registered in the UK during the week to 13

Pfizer becomes first Covid vaccine to gain full FDA approval

By [Bernd Debusmann Jr](#)
BBC News, Washington

🕒 2 days ago




- Misinformation about COVID-19 and vaccine appears to have gotten worse, driving and increase in case
- Another wave of outbreak emerge across the world dominated by Delta variant, especially in UK and US
- Pfizer become the first COVID-19 vaccine to gain full FDA approval
- FDA has not approved Ivermectin to treat COVID-19

World's Data

> **217 Million**
Confirmed Cases 

> **4,5 Million**
Death Cases 

> **520,000**
Daily New Cases 




Number of daily confirmed cases have slowly increased since the last lowest number in early June 2021
Worldometer; August 30th, 2021

COVID-19 Case Around the Globe

Countries with highest cases in Asia


Number of cases per day from Jan 2020 to 22 Aug 2021, seven-day rolling average. Each country on its own scale



Source: Johns Hopkins University, national public health agencies **BBC**

Countries with highest cases in Middle East


Number of cases per day from Jan 2020 to 22 Aug 2021, seven-day rolling average. Each country on its own scale



Source: Johns Hopkins University, national public health agencies **BBC**

Countries with highest cases in Europe

Number of cases per day from Jan 2020 to 22 Aug 2021, seven-day rolling average. Each country on its own scale




Note: French government data revised down on 20 May, affecting rolling average

Source: Johns Hopkins University, national public health agencies **BBC**

Countries with highest cases in Africa


Number of cases per day from Jan 2020 to 22 Aug 2021, seven-day rolling average. Each country on its own scale



Source: Johns Hopkins University, national public health agencies **BBC**

Countries with highest cases in Latin America & Caribbean

Number of cases per day from Jan 2020 to 22 Aug 2021, seven-day rolling average. Each country on its own scale



Source: Johns Hopkins University, national public health agencies **BBC**

- COVID-19 is still a big problem for most of the countries in the world as it still actively spreading and infecting many people
- In general, each countries have similar pattern where they keep reaching another peak after having lowest rate for sometimes
- Other than vaccination, maintaining healthy protocol is still the main key to prevent the spreading of COVID-19

COVID-19 DASHBOARD: INDONESIA CURRENT SITUATION

As of 31 August 2021



4,079,267
Confirmed Cases

132,491
Death Cases
(3,2% of Confirmed)

203,060
Active Cases
(5,0% of Confirmed)

3,743,716
Recovered
(91,8% of Confirmed)

251,951
Suspects

COVID: Why Indonesia is unable to rein in the pandemic

Bali, Yogyakarta Regions Remain at PPKM Level 4

Translator: **Dewi Elvia Muthiariny**
Editor: **Petir Garda Bhwana**

24 August 2021 06:47 WIB



Indonesia's Covid-19 Mortality Rate Higher than Global Average

Translator: **Dewi Elvia Muthiariny**
Editor: **Petir Garda Bhwana**

25 August 2021 11:26 WIB

Deadly COVID-19 Variant Migrates to Indonesia's Outer Islands

Just as cases are beginning to ease in densely populated Java and Bali, they are rising elsewhere.

Jokowi Says Covid-19 Daily Cases May Reach 400,000 If Not Contained

Translator: **Dewi Elvia Muthiariny**
Editor: **Petir Garda Bhwana**

26 August 2021 12:21 WIB

Devastated Indonesian parents mourn children lost to COVID-19

The archipelago has seen a surge in child deaths since the Delta variant took hold in July.



Indonesia's huge coronavirus outbreak could be the perfect breeding ground for the world's next variant

Herd Immunity Requires Higher Vaccination Rate, Says IDI Expert

Translator: **Ricky Mohammad Nugraha**
Editor: **Laila Afifa**

25 August 2021 22:15 WIB




- Indonesia COVID-19 death number is the highest worldwide despite of active case reduced
- Experts believe that Indonesia have the highest chance on creating new mutation due to big numbers of confirmed covid-19 case among its population
- COVID-19 spreading to outer island and isolated places in Indonesia, where healthcare facilities are limited
- Indonesia start to give booster vaccine (3rd dose) for all healthcare workers

Newly Watched Indonesia COVID-19 “Super Strain” and It’s Potential to Run Wild and Cause 3rd Wave Outbreak

New WHO labels for Covid-19 variants

The UN health agency uses letters of the Greek alphabet to avoid stigmatising nations where they were first detected



Legend: Date identified Earliest recorded samples

VARIANTS OF CONCERN

Increase in transmissibility or virulence

α	β	γ	δ
Alpha B117	Beta B1351	Gamma P1	Delta B16172
Dec 18, 2020	Dec 18, 2020	Jan 11, 2021	May 11, 2021
United Kingdom	South Africa	Brazil	India

VARIANTS OF INTEREST

Can cause community transmission or multiple clusters, or detected in multiple countries

ϵ	ζ	η
Epsilon B1427/B1429	Zeta P2	Eta B1525
March 5, 2021	March 17, 2021	March 17, 2021
United States	Brazil	Multiple countries

θ	ι	κ
Theta P3	Iota B1526	Kappa B16171
March 24, 2021	March 24, 2021	April 4, 2021
Philippines	United States	India



Source: AGENCE FRANCE-PRESSE
STRAITS TIMES GRAPHICS

Home » Website » National » Covid-19 Third Wave Likely To Hit India By August End: ICMR

Covid-19 Third Wave Likely To Hit India By August End: ICMR

ASIA - PACIFIC, LATEST ON CORONAVIRUS OUTBREAK

Indonesia registers 3 cases of Delta Plus variant of COVID-19

Country reports 47,791 COVID-19 cases, 1,824 fatalities over past 24 hours

News | Coronavirus pandemic

Indonesia: Raging pandemic offers fertile ground for new variants


Experts keeping a close eye on developments as double-digit test positivity rate suggests outbreak out of control.

“By August, the WHO European Region will be “delta dominant”, but by August the region will not be fully vaccinated (63% of people are still waiting for their first jab) and in August the WHO European Region will still be mostly restriction-free, with increasing travels and gatherings,” Dr Kluge said.

WHO insist that vaccines ARE effective against the delta variant, but two doses are required.

Extremely high cases, positivity rate, low vaccination in Indonesia makes for the perfect place for new virus variant to emerge and multiply, causing possible third wave.



Indonesia Bed Occupancy Rate




1. 6 Provinces with BOR > 40% : **Bali (58%), Aceh (51%), Bangka Belitung (48%), South Kalimantan (44%), East Kalimantan (43%), Central Sulawesi (42%)**
2. 14 Provinces with BOR 26-40%
3. 14 Provinces with BOR < 25%
4. **DKI Jakarta, Central Java and West Java** are on the 10 lowest bed occupancy for the first time in August 2021

Source: Kemkes 30 August 2021

Indonesia COVID-19 Map



Risk Zone Indonesia



- Red zone / high risk area reduced to 10%, spreading across Indonesia
- Moderate risk area are increasing as well as low risk. This indicates that Covid-19 is still spreading rapidly and reaching remote areas
- Despite of declining bed occupancy rate in Java Island, other part of Indonesia especially remote area are now still in a great danger of COVID-19 spreading due to its challenging access towards proper covid testing, treatment, and medication
- The declining rate of bed occupancy in some places also affected by the lower rate of covid testing

Source: covid19.go.id/ August 2021

Siloam Hospitals is well equipped to treat Covid-19 patients around Indonesia

SILOAM HOSPITALS COVID-19 TOTAL OPERATIONAL BED ALLOCATION
As of 31 August 2021



COVID-19 DASHBOARD: SILOAM DASHBOARD

As of 31 August 2021

Total COVID Patients


31,601

Current Hospitalized
COVID Patients

286



COVID-19 Patient and Mortality Rate



- Current Siloam Hospitals COVID patients has decreased since the last spike in July which caused 100% bed occupancy rate and highest mortality rate at 14%.
- As a referral hospital with highest no. of ICU beds, Siloam mortality rate is relatively higher due to higher severe cases compared with other C19 facilities.



COVID-19 Testing




Indonesia's testing volume has not achieved national target of 324.283 people tested/day during PPKM

INDONESIA COVID-19 TESTING

2 Mar 2020 – 31 Jul 2021

People Tested Weekly Positivity Rate 7 per. Mov. Avg. (People Tested)



- Number of reported people tested have started to decrease within the last 2 weeks
- As of 31 July 2021, only 7% (17.8mn people) of Indonesia population were tested for Covid
- As of 31st August 2021, Indonesia positivity rate reach 17,38% (excluding Antigen Test) or 8,07% (including Antigen Test)

COVID-19 Testing: PCR and Quantitative Antibody

PCR Swab Test

Rp495.000

Java & Bali area

Rp525.000

outside Java & Bali area

Pre-register through **MySiloam** app or siloamhospitals.com to secure your appointment

*Results will be available within 24 hours after the sample is received by the laboratory
Prices are valid from August 18th 2021

For further information, please contact:
1-500-181



Swab PCR Express

MONEY BACK GUARANTEED 100%

6 hours result
Rp1.399.000
PCR Platinum Package**

12 hours result
Rp900.000
PCR Gold Package**



* Appointment through **MySiloam** application and siloamhospitals.com or scan the following QR code

** Including PCR test and vitamin



Test result is connected to NAR (New All Record) and pedulindunglid



Ambulance 1-500-911 | Appointment 1-500-181
www.siloamhospitals.com

PASTIKAN KESEHATAN ANDA SEBELUM DAN SETELAH DIVAKSIN BERSAMA SILOAM

Paket Skrining Pra Vaksinasi Basic
Rp 399.000*

- Skrining hipertensi
- Tes antibodi kuantitatif
- Tes HbA1c
- Konsultasi dokter

Paket Skrining Pra Vaksinasi Premium
Rp 899.000*

- Skrining hipertensi
- Tes antibodi kuantitatif
- Tes darah lengkap
- Tes HbA1C
- Tes tiroid (TSH Sensitive dan FT4)
- Konsultasi dokter

*Pemeriksaan minimal H-1 sebelum waktu vaksin

Paket Skrining Pasca Vaksinasi
Rp 599.000*

- 3x tes antibodi kuantitatif
- 1x pemeriksaan tanda vital
- 1x konsultasi dokter

Dapatkan harga khusus untuk pembelian melalui mcu.siloamhospitals.com



ARE YOU SURE YOUR ANTIBODY IS STRONG ENOUGH TO FIGHT COVID-19?

Check your antibody level with **QUANTITATIVE ANTIBODY TEST!**

QUANTITATIVE ANTIBODY TEST PACKAGE

Rp299.000

- Quantitative antibody test
- Doctor consultation
- Test result

Get a special price when purchase through siloamhospitals.com/mcu



- Recommended for:
- COVID-19 survivors
 - Before and after vaccination
 - Determining total antibody level of SARS-CoV-2 in the blood
 - Potential donor for plasmapheresis/convalescent plasma therapy

For further information, please contact:
1-500-181



Harga Baru

Rapid Antigen

Rp99.000

Java & Bali

Rp109.000

Luar Jawa & Bali

Lakukan pre registrasi melalui aplikasi **My Siloam** atau siloamhospitals.com dengan scan kode QR ini



Berlaku mulai 6 September 2021
Melayani tes swab untuk grup, korporasi, dan acara
Informasi lebih lanjut, hubungi
1-500-181



Call Center: 1-500-181, Emergency: 1-500-911
Click here to [unsubscribe](#) from our emails.

• COVID Testing provided by Siloam Hospitals already approved by Japan Embassy.






COVID-19 Vaccination



Number of People Vaccinated Against COVID-19



Source: Official data collated by Our World in Data. This data is only available for countries which report the breakdown of doses administered by first and second doses in absolute numbers.
CC BY


Indonesia aims to vaccinate 208.2 million people within a year as an effort to reach herd immunity

INDONESIA VACCINATION
13 Jan 2021 – 31 Jul 2021

Vaccination progress is the slowest among the elderly



Latest 7-day daily average for 1st dose was at 698,723 vaccinations



- As of 31 July, 23% (people vaccinated/target vaccinated) progress achieved to reach herd immunity

Indonesia Vaccination Progress Breakdown as of 31 August 2021

Healthcare Workers

1.468.764

1st Dose




112,38% (1,650,527)

2nd Dose



104,19% (1,530,369)

3rd Dose



43,58% (640,089)

Elderly

21.553.118

1st Dose



24,54% (5,288,325)

2nd Dose



17,44% (3,758,348)

Public Service Officer

17.327.167

1st Dose



193,79% (33,578,339)

2nd Dose



110,91% (19,216,923)

Public and Vulnerable People


141.211.181

1st Dose



13,78% (19,459,990)

2nd Dose




6,56% (9,261,732)

Age of 12 – 17 years old


26.705.490

1st Dose



9,97% (2,662,732)

2nd Dose



6,63% (1,769,762)

Siloam Hospital's Continuous Effort: Vaccination

(As of August 31th)

Government
Vaccination Program

Gotong Royong
Vaccination

>240,000

Total Vaccines for public



Terms and Condition for Foreigner Vaccination

1. Teacher
2. Lecturer
3. Educational support officers
4. Elderly (>60 years old)
5. Lived in vulnerable area:
 - 445 district according to Pergub no. 90/2018
 - 21 villages according to Kepgub no. 878/2018
 - District with high virus mutation potential
 - Red and Orange Zone Sub Districts according to weekly update on www.corona-Jakarta.go.id


Foreigners who meets the criteria must own SKTT or KTP WNA
You may check SKTT or KTP WNA registration at silaporlagi-dukcapil.Jakarta.go.id

- We have successfully given more than 240.000 dose of vaccines for our frontliners as well as for public until August 2021
- Gotong Royong Vaccination Program has kicked off since 18 May 2021 and Siloam Hospitals contributed by giving nearly 73.000 dose of vaccine to registered companies
- As of 29 August, Siloam Hospitals given nearly 7.200 doses of booster vaccine (3rd dose) for our frontliners

Countries' Cases Growth v.s. Vaccination Progress


INDIA

1 Sep – 31 Jul 2021




ISRAEL

1 Sep – 31 Jul 2021




SINGAPORE

1 Sep – 31 Jul 2021




UK

1 Sep – 31 Jul 2021




USA

1 Sep – 31 Jul 2021



JAPAN


1 Sep – 31 Jul 2021



- As of 31 July, 28.4% of the world population has received COVID vaccine

SOURCE: OURWORLDINDATA, KAWAL COVID, TELEGRAPH, BBC

Infection and Hospitalization Rate by Vaccination Status (CDC)



Infection rate:




Hospitalization rate:



Mortality rate:



■ Unvaccinated ■ Partially Vaccinated ■ Fully Vaccinated



Source: CDC 24 August 2021 / Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021

- The findings in this report indicating that COVID-19 vaccination protects against severe COVID-19
- Efforts to increase COVID-19 vaccination coverage, in coordination with other prevention strategies, are critical to preventing COVID-19–related hospitalizations and deaths.

Hospitalization Rate by Vaccination Status (Siloam Hospitals)

Covid patients in hospitals:



In wards:



In HCU/ICU:



- Most (62%) of the hospitalized patients were unvaccinated
- 21% of the hospitalized patients were breakthrough cases
- Most of HCU/ICU admissions (72%) were among patients who were unvaccinated
- Vaccination provides some protection to prevent critical disease, although still at lower rate than other countries with higher vaccination coverage

No. of sample : 408,
As of August 2021

■ Unvaccinated ■ Partially vaccinated ■ Fully vaccinated ■ Unknown

COVID-19 Vaccine Efficacy: What Studies Show

THE LANCET
Microbe

COVID-19 vaccine efficacy and effectiveness




Figure: RRR and NNV with 95% CI ranked by attack rate in the unvaccinated (placebo) group for five COVID-19 vaccines
The lower the NNV and the higher the RRR, the better the vaccine efficacy. Details are in the appendix (p 3).
RRR=relative risk reduction. NNV=numbers needed to vaccinate. NIH=US National Institutes of Health.


Olliaro P, et al. 2021.

Effectiveness Against Variant of Concern

Vaccine Name	Variant of Concern				
	Original Virus	Alpha (B.1.351)	Beta (B.1.1.7)	Delta (B.1617.2)	Gamma (P.1)
Pfizer	90-95%	83-95%	90-95%	88-96%	90-95%
AstraZeneca	76-85%	76-86%	76-85%	71-92%	76-85%
Moderna	86-94%	< Original	86-94%	-	-
Johnson & Johnson	72-86%	64-85%	64-82%	< Original	-
Novavax	90-91%	60%?	< Original	< Original	-
Sinovac	50-60%	< Original	50-60%	< Original	-

Source: NEJM, Yale Medicine, BMJ, Business Insider, Pubmed, 2021.

Effectiveness Against Hospitalization (Public Health England, 2021)



Most studies from the US and the UK focus on mRNA vaccine (Pfizer-BioNTech and AstraZeneca Vaccine). More studies still needed on the efficacy of these vaccines against variant of concern, especially other type of vaccines.

COVID-19 Vaccine Booster Shot: What We Know So Far

Covid: UK vaccine booster scheme likely to start in September - Sajid Javid

Pfizer seeks U.S. approval for COVID vaccine booster

COVID-19 booster shots can help vulnerable, WHO Europe head says

COVID VACCINES

Turkey starts giving a fourth jab to travelers for vaccine passports

Many countries won't recognize Sinovac, which was widely administered by Ankara

Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

Media Statement

For Immediate Release: Wednesday, August 18, 2021
 Contact: [Media Relations](#)
 (404) 639-3286


The British Medical Journal study showed 75 participants who had their first two doses at 16 weeks apart were assessed. Preprint report showed antibody levels 28 days after the third dose were significantly higher than 28 days after the second dose

Antibody titer 28 days after 3rd dose is 2x higher than 28 days after the 2nd dose (3rd dose: 3746 tlgG EU vs 2nd Dose: 1792 tlgG EU)

Turkey is already starting their 4th dose for vaccine for travelers (As some countries require two doses of the Pfizer-BioNTech vaccine for entry), while 3rd dose vaccine still considered in Europe and US. Indonesia also already started its booster shots for healthcare workers

Share of people vaccinated against COVID-19, Aug 30, 2021

+ Add country



Source: Official data collated by Our World in Data. This data is only available for countries which report the breakdown of doses administered by first and second doses in absolute numbers.

Our World in Data


NEWS • NATIONAL

Indonesia begins to give third COVID-19 shots to 1.5 million health workers

COVID-19 vaccine doses administered per 100 people

Total number of doses administered, divided by the total population of the country.

LINEAR LOG



Source: Official data collated by Our World in Data. For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses

Indonesian Health Minister on August 2 stated Indonesia will start for 3rd dose of COVID-19 Vaccine

Govt Plans to Give Vaccine Booster for General Public in 2022

Translator: [Ricky Mohammad Nugraha](#)
 Editor: [Laila Afifa](#)
 6 August 2021 14:31 WIB
 July 27, 2021 7:15 PM WIB
 Last Updated a month ago

Healthcare & Pharmaceuticals
Indonesia considers COVID-19 booster shots for wider use -govt official

Speeding up the 1st and 2nd dose vaccination to increase vaccination coverage will be more beneficial in Indonesia in order to reach herd immunity. However, booster dose are needed for all healthcare workers due to high risk of infection transmission.

Siloam Hospital's Continuous Effort: 3rd Vaccination

3rd Dose Covid Vaccine for Health Professionals and Allied Health workers



Start

- 16 July 2021 in Indonesia
- 3 August 2021 started in Siloam



Goal

- 3rd dose vaccination health professionals and allied health workers



Vaccine Brand

- Moderna (mRNA Vaccine)


Terms and Condition

- Health Professionals and allied health workers
- Had completed 1st and 2nd dose vaccination
- Have at least 3-6 months after 2nd dose vaccination



Progress

- Siloam has administered 7100+ doses for Health Professionals and Allied Health workers for 3rd vaccination





COVID-19 Treatment: Monoclonal Antibody

Monoclonal Antibodies



What are antibodies?

Antibodies are naturally made in our bodies to fight infection.



What are MONOCLONAL ANTIBODIES?



Monoclonal antibodies (**mAbs**) are antibodies developed in a laboratory to help our bodies fight infection.

Nearly **100**

mAbs are FDA approved to treat health conditions including cancers and autoimmune diseases.



mAbs are also being studied for the treatment and prevention of COVID-19.




How are mAbs administered?



mAbs are given through intravenous infusion (i.e., through a vein) or injection.

OR




How often infusions or injections of mAbs are needed depends on the specific mAbs.


What are common side effects of mAbs?



Allergic reactions Flu-like Symptoms Nausea & Vomiting Diarrhea Low blood pressure



COVID-19
Prevention Network
PreventCOVID.org



Monoclonal antibody treatment is available to individuals who:

- Are high risk** for developing severe COVID-19 and
- Have a positive COVID-19 test and have not yet been admitted to the hospital and
- Are 12 years of age or older (and at least 88 pounds)

It had initially targeted hospitalized patients. But in mid- August, it started allowing patients isolating at hotels and temporary medical facilities to receive the treatment subject to certain conditions, as it is getting difficult for them to find a vacant hospital bed – *NHK World, Japan*


Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 – *Cision PRNews*

COVID-19 Treatment: Celltrion's Regkirona (Regdanvimab)

- **Early February 2021** – South Korea Ministry of Food and Drugs Safety (MFDS) grant a Conditional Marketing Authorization (CMA) for the emergency use of Regdanvimab.
 - **9 – 12 July 2021** – Full phase III data at the 31st European Congress of Clinical Microbiology and Infectious Disease (ECCMID) showed it can significantly reduce the risk of COVID-19 related hospitalization or death by 72% for patients at high risk or progressing to severe COVID-19 and 70% for all patients.
 - **17 July 2021** - Indonesia's National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan) has granted emergency use approval for its treatment to be used on patients with mild symptoms or with underlying conditions among patients older than 50. For those under 50, Regkirona can be used on patients with severe symptoms only.
- Celltrion has also submitted requests for emergency use authorization (EUA) of the antibody in several other countries: Malaysia, India, Brazil, Mexico, Canada, Jordan, Saudi Arabia, UAE.
- In the US, Celltrion is having a preliminary discussion with the Food and Drug Administration (FDA) regarding the regulatory filing.



Source: BioPharma-reporter.com/19 July 2021



Mechanism

- Regkirona™ related to RBD spike SARS-CoV-2 and prevent the interaction with cellular receptor, angiotensin converting enzyme 2 (ACE2).
- By avoiding virus to enter the cell and causing SARS-CoV-2 infection, Regkirona™ are able to minimize acute case and shorten the recovery time.

COVID-19 : Proper Self Isolation

Who is Eligible for Self Isolation

Those who didn't meet all the criteria below eligible for self isolation / consultation to nearest healthcare / teleconsultation


Symptoms

- Shortness of breath with or without fever, tiredness, or loss of smell
- Have comorbid that required observation

Condition

- Respiratory Rate >20x per minute
- Oxygen saturation <95%
- Tested (+) for antigen or PCR test


What to do During Isolation



Good ventilation and lighting



Separate bathroom or routine disinfectant on frequently touched surface



Separate bedroom



Use separate tools for eating, drinking, shower

When to go to Hospital

Oxygen Saturation Level

95-100 In a good condition

93-94 Bed rest needed to increase oxygen level

<92 Need to go to hospital for doctor's treatment

<80 Ventilator needed

PERAWATAN ISOLASI MANDIRI DI RUMAH

New Price
Harga berlaku per 19 Juli 2021

	C19 Isoman Silver Rp 999.000 per hari*	C19 Isoman Gold Rp 1.799.000 per hari*
Periode paket	10 hari	14 hari
Telekonsultasi dokter spesialis	1x	2x
Telekonsultasi dokter umum	1x	-
Kunjungan perawat	2x	10x
Telekonsultasi perawat	6x	2x
RT-PCR	Same day	Same day
CT Scan Toraks**	1x	1x
Tes laboratorium	1x	1x
Vitamin (oral dan injeksi)	1x	1x
Pulse oxymeter	1 unit	1 unit

* Paket harga diambil sesuai periode paket. Penambahan untuk orang ke-2 dan seterusnya: Rp 1.000.000 (10 hari) dan Rp 1.400.000 (14 hari) per hari.
** Ditentukan di rumah sakit.

Spesial & layanan berkelas

Pendaftaran untuk area Jakarta, Tangerang, dan Lippo Cikarang silakan scan kode QR atau klik link berikut:



silam.com/termal01H

Jam operasional: Senin - Jumat (08.00 - 17.00)



Siloam Hospitals


Siloam Hospitals Lippo Village
Jl. Siloam No. 6, Lippo Village, Tangerang
(021) 8094 6900

Reservasi: 1-800-011 | Pasca Rawat Jalan: 1-800-181
www.silamhospitals.com

REPORT POSITIVE CASE HONESTLY TO ALLOW FOR PROPER CONTACT TRACING

GLOBAL: Many patients exhibit persistent or new symptoms more than four weeks after first being diagnosed with COVID-19


Nearly one-fourth of patients with COVID-19 experience post-acute sequelae of SARS-CoV-2 infection (PASC)



Source: A FAIR Health White Paper, June 15, 2021


- 49.98% hospitalized patients experienced at least one post-Covid condition
- The 5 most common conditions: pain (5.1%), breathing difficulties (3.5%), hyperlipidemia (3%), malaise & fatigue (2.9%), hypertension (2.4%)

Google web search with keyword "Long Covid" has increased globally since March 2020 up until now.



Source : [Google Trends](#)


Multi-organ complications of COVID-19 and "Long Covid"



Source : [BMJ](#), 2021

INDONESIA: The majority of COVID-19 survivors in Indonesia experience Long Covid symptoms

63.5% of Covid-19 survivors in Indonesia experience long Covid symptoms




n : 463

Source: [FKUI-RS Persahabatan](#)

- The 5 most common post covid conditions: malaise & fatigue (30.24%), cough (16.85%), muscle pain (11.23%), headache (11.23%), sleep disorder (9.72%)
- Currently, Long COVID-19 is still being studied to monitor its progress.

Google web searches "Long Covid" began to increase significantly in June 2021 and reached its peak in mid-July correlated with the peak of covid cases in Indonesia



*Numbers represent search interest relative to the highest point on the chart for the given region and time.

Source : [Google Trends](#)

Government and health institutions are starting to actively raise awareness of "Long Covid" through education and webinars



Source : [Kemenkes RI](#)



Source : [RSA UGM](#)

Yakin Tubuh Sehat Pasca Terinfeksi COVID-19?

Pastikan Secara Menyeluruh untuk Keamanan Diri dan Sesama

- 📄 **MCU After COVID-19 Basic** Rp 2.500.000
Konsultasi dokter, titer antibodi, rontgen toraks, EKG, paket cek laboratorium pasca COVID-19 dasar
- 📄 **MCU After COVID-19 Advanced** Rp 4.000.000
Konsultasi dokter, titer antibodi, CT Scan toraks, EKG, paket cek laboratorium pasca COVID-19 lengkap
- 📄 **MCU After COVID-19 Pro** Rp 5.000.000
Konsultasi dokter spesialis, konsultasi dokter *medical check up*, titer antibodi, rontgen toraks, EKG, paket cek laboratorium pasca COVID-19 komprehensif

Kunjungi mcu.siloamhospitals.com untuk detail paket

Hemat 10% untuk pembelian melalui mcu.siloamhospitals.com dengan mencantumkan kode kupon **PASCACOVID** sebelum pembayaran



MRCGC Siloam Hospitals Semarang
Jl. Garnisun Kav. 2-3 Karet Semanggi, Jakarta Selatan
(021) 2996 2888

Reservasi
1-500-9111
www.siloamhospitals.com

What Do I Do (WDID) MATRIX

Preventing C19 Infection

- Individual Level
 - Upgrade Health Protocols
 - Vaccination
 - Boost Immune System
- Corporate Level
 - Renew Regulations
 - Tighten Protocols
 - Routine Screening
 - Vaccination

During C19 Infection

- Individual Level
 - Proper Self Isolation
 - Know the Red Flags
 - Be honest (report if positive)
- Corporate Level
 - Provide Employee Care Services (Hospital or Self Isolation Access)
 - Telemedicine Consultation
 - Contact Tracing

Post C19 Infection

- Individual Level
 - Keep doing health protocols
 - Continue vaccination
 - Follow up examination & Rehabilitation for complications
- Corporate Level
 - Adjustment of Work (if needed)
 - Employee rehabilitation programs



THANK YOU

事前質問・良くあるご質問 ①

【質問タイプ1：新型コロナウイルスワクチンと検査について】

- ① シノバック製のワクチンを接種した場合、抗体は6か月間しか持続しないか？
→シノバック製ワクチンに限らず、抗体量は時間の経過を経て徐々に減少していく事が各研究結果から示されております。持続期間は個人差があるものの、約3-6ヶ月間と考えられております。
- ② 定量抗体検査を実施する事で、ワクチンの有効性を証明できるか？
→定量抗体検査を通じ、ワクチン接種後にどの程度の抗体が出来たかを定量的に認知する事が可能です。シロアム病院でも同検査 (*Paket Antibodi Kuantitatif*) を提供しておりますので、ご興味をお持ちの方は最寄りのシロアム病院窓口にお問い合わせ下さい。
- ③ 過去に感染した人もワクチンを接種すべきか？
→新型コロナウイルスは感染歴がある場合も再感染のリスクがある事から、ワクチン接種を推奨しております。
- ④ シノバック製のワクチンは従来の中国株のコロナウイルスに対する予防・重症化を防ぐのに効果があるという認識でいるが、その他の変異株に対してどの程度予防効果・重症化を防ぐ効果があるか？
→未だ研究が進んでいる状況ですが、参考データとしてP21のスライドをご参照ください。
- ⑤ シロアム病院では個人の有料ワクチン接種プログラムを実施しているか？または、そのようなプログラムを今後実施する予定はあるか？
→シロアム病院として提供している有償プログラムは法人向けの民間自主接種プログラム (*Vaccine Gotong Royong*) のみで、個人向けの有償ワクチンプログラムは実施しておりません。今後同サービスの提供を開始する場合は、改めてご案内をさせていただきます。
- ⑥ モデルナ、乃至はファイザー製のワクチン接種をするにはどうしたら良いか？
→政府主導のワクチンプログラムにおいて、中国製・アストラゼネカ製のワクチンを諸事情で接種出来ない方に限り、医師の診断書の提示を条件にモデルナ製ワクチンの接種が進められております。但しワクチン未接種の人々が対象で、外国人の場合は更に制限 (P17をご参照下さい) が存在しますのでご注意ください。
- ⑦ 中国製以外のワクチンを接種するにはどうしたら良いか？
→在インドネシア日本国大使館主導による、在留邦人向けワクチン接種プログラムにてアストラゼネカ社のワクチン接種が可能で御座います。詳細は在インドネシア日本国大使館ウェブサイト (https://www.id.emb-japan.go.jp/oshirase21_170.html) をご参照ください。
*同プログラムは、既に応募を終了しております。

事前質問・良くあるご質問 ①

【質問タイプ1：新型コロナウイルスワクチンと検査について】

- ⑧ シノバック製ワクチンと、シノファーム製ワクチンの違いは何か。また、その有効性について。
→本質的にはどちらも同じタイプの不活化ワクチンとなります。P21のスライドにも記載した通り各ワクチンとも十分な有効性は証明されており、またP20のスライドに記載の通り、両中国製ワクチンともインドネシアにおける重症化・非入院化の予防に効果を発揮していると考えられます。
- ⑨ インドネシア国内での一般向け3回目接種の実施可否、実施の場合、実施予定日。
- ⑩ ファイザー製ワクチンを日本で2回接種後、インドネシアで3回目接種可のワクチンの種類および2回目接種日から空ける期間。
→（⑨と⑩を合わせて回答致します）インドネシアにおいては、現在医療従事者のみが3回目接種の対象となっております。
政府方針として一回目の接種が完了していない国民（特に地方都市や島嶼部等）向けのワクチン接種を優先する方針なので、外国人を含む一般国民への3回目接種は早くも22年第一四半期からの開始になると推察しております。

事前質問・良くあるご質問 ②

【質問タイプ2：現在の病床稼働率、入院の可否について】

- ① 外国人（駐在員）も現在入院が可能な状況か？
→KITASの有無に関わらず、現在はいかなる外国人も入院の受入れが可能で御座います。
- ② シロアム病院における、コロナ患者を受け入れられる病院のキャパシティを教えてください。
→ジャカルタ都市圏では、以下の3病院をコロナ専属病院として約400の病床を構え運営しております。
 1. Siloam Hospital Mampang (南ジャカルタ), Tel: 0811-1959-2397
 2. Siloam Hospital Kelapa Dua (タンゲラン), Tel: 0852-1133-2181
 3. RSUS (タンゲラン), Tel: 021-8064-6900, Emergency: 1-500-911
- ③ ジャカルタの病床稼働率を教えてください。
→P6のスライドに記載の通りジャカルタは17%、シロアム病院は約60%となります。シロアム病院の稼働率が高いのは、ICU病床を多く構えている事より、他の医療機関からの重症患者受入れが多くある事が背景になります。
- ④ コロナに感染して深刻な症状が出た場合、入院するにはどのような手順を踏めばよいか？
→上記コロナ専属病院の緊急外来 (24時間・365日対応可) にご連絡、乃至は直接お越してください。まずは医師にて診断、検査、初期的治療等を実施した上で、状況に応じて入院を含めた治療のご案内をさせていただきます。
- ⑤ モデルナ接種には医者からのシノバックとアストラゼネカが接種出来ない証明が必要と理解しているが、どのような方が対象に証明書が発行されるのか？
→重い急性疾患にかかっていたり、ワクチン成分に対し重度の過敏症の既往歴のある方等が対象になります。該当されると思われる方は、ワクチン接種前に医師にご相談頂く事をお勧めいたします。
- ⑥ 治療/入院中に重症化あるいは不幸にも死亡に至った場合、治療/診療記録はどこまで、どうやって、病院に開示を求められるか？
→ご不幸にもお亡くなりになった場合は、死因・日時等が記載された死亡証明書と、診療記録の要約をお渡しいたします。何か特別なご要望が有る場合は個別に対応をさせていただきますの、ご遠慮なく病院の担当者にお申し付けください。
- ⑦ コロナ患者に対してどのような治療が提供可能か？
→個々人の状況（軽症・中等症・重症）に基づき治療方針を決定します。P27のスライドに記載の通り、インドネシアでもモノクローナル抗体療法が緊急承認され、シロアム病院でも同治療の提供を開始しております。
- ⑧ コロナ陽性判定後に推奨する手続き・手順を教えてください。
→まずは医師にご相談を頂き、状況をご説明の上で治療方針（再検査・在宅療法、入院等）の判断を仰いで頂く事を推奨致します。

事前質問・良くあるご質問 ③

【質問タイプ3：今後の動向について】

- ① コロナ感染のトレンドと、病床（一般/ICU）稼働率の見通しについて教えてほしい。
- ② 感染者と病床占有率の相関関係と、21年7月度のような感染急拡大が再度発生する可能性は有るか教えてほしい。
→（①と②を合わせて回答致します）次ページの、インドネシアにおける新型コロナウイルス感染者数の推移も併せてご参照ください。
インドネシアでは2020年3月に最初の感染者を確認してから今日に至るまで、計3回の感染急拡大が発生しております。
 - Peak 1：2020年9月下旬（独立記念日含む、休暇シーズンを背景とした人流増後）
 - Peak 2：2021年1月下旬-2月上旬（年末年始の休暇シーズンを背景とした人流増後）
 - Peak 3：2021年7月下旬（レバラン休暇シーズンを背景とした人流増後、並びにデルタ株蔓延のタイミング）

これまでの推移を考察すると、感染拡大は季節要因でなく大型休暇の後に発生している事が読み取れるかと思えます。また、感染者数の増加に伴い病床稼働率も上昇し、特に21年7月度のピーク時には入院が必要な患者様用の病床確保が容易でなかった事は皆様のご認識の通りで御座います。

一方でPSBB/PPKMといった行動制限の導入・強化実施後は、感染者数の抑制に成功しており、足元も少しずつ新規感染者数は減少しているのも事実です。次回の大型連休となる年末年始や、翌年のラマダン時期には再度感染者数が増加する可能性は考えられますが、国民の間でワクチン接種が進んでいる事により、入院が必要な重症者数の割合は減少（在宅療法で対応可能な軽症患者の割合が増加）すると推察しております。

【質問タイプ4：その他】

- ① インドネシアにおける子供の感染状況、シロアムで児童向けにどのような治療が出来るか
→子供の感染リスクは高く、21年7月のピーク時には一時新規感染者の12.5%（=8人に1人）が子供でした。現在では12歳以上にもワクチン接種が進められており、治療に関しては成人と同じ治療法が適用されています。
- ② 感染してからワクチン接種をするのに、なぜ3か月の間待つ必要があるのか
→感染後3ヶ月は抗体が確認できるという調査レポートが出ている事、またワクチン供給量が限られている中で早急に集団免疫を獲得する目的から、保健省によって定められたガイドラインになります。


上記の各回答は、2021年9月1日時点で入手可能な政府公表情報・方針・各種研究データ等に基づいたものになります。

その他、本資料に関するお問い合わせやご不明な点等が御座いましたら、

ご遠慮なく笠井（TEL:+62-8118562762, E-mail: hiroshi.kasai@silohospitals.com）までお問合せ下さい。

Travel Status - Background

Background: travel status should affect people behaviour for travelling which should impact the **spread of COVID-19** :
The tighter the restrictions, the smaller the transmission rate, the higher doubling rate, the less the number of new cases



- Tendency in increasing cases **post holiday season**
- **Tight restriction** after the cases start to increase